Home › NDC Lookup › RxCUI directory › RxCUI 2668051

Etrasimod 2 MG Oral Tablet — RxCUI 2668051

RxNorm drug concept · Semantic clinical drug
RxCUI 2668051 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2668051
Official nameEtrasimod 2 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asetrasimod 2 MG (as etrasimod arginine 2.76 MG) Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)350 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Etrasimod 2 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Etrasimod 2 MG Oral Tablet RxCUI 2668051

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Etrasimod 2668045
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Velsipity 2668052
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Etrasimod Oral Tablet 2668050
    • Etrasimod Oral Product 2668048
    • Etrasimod Pill 2668049
    • Etrasimod Oral Tablet [Velsipity] 2668056
    • Velsipity Oral Product 2668054
    • Velsipity Pill 2668055
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Etrasimod 2 MG SCDC · 2668047
  • Etrasimod Oral Tablet SCDF · 2668050
  • Etrasimod Oral Product SCDG · 2668048
  • Etrasimod Pill SCDG · 2668049

Brand-Name Concepts

  • Etrasimod 2 MG Oral Tablet [Velsipity] SBD · 2668057
  • Etrasimod 2 MG [Velsipity] SBDC · 2668053
  • Etrasimod Oral Tablet [Velsipity] SBDF · 2668056
  • Velsipity Oral Product SBDG · 2668054
  • Velsipity Pill SBDG · 2668055
  • Velsipity BN · 2668052

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2668051 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0274-30 1 BOTTLE in 1 CARTON (0069-0274-30) / 30 TABLET, FILM COATE... Velsipity Pfizer Laboratories Div Pfizer Inc 2023-10-19
Observed labelers: Pfizer Laboratories Div Pfizer Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.